Apiman vs ReadMe

Apiman is open-source API management software for securing API access and handling discovery and governance across the API lifecycle. Its policy-based runtime governance supports multiple plans with different service levels for the same API. The management layer includes a REST API, Manager UI, and standalone Developer Portal, along with multi-tenancy, events, notifications, permissions, and approvals. Teams can create custom policies and components with Java plugins, which can be loaded at runtime without restarting. Gateways scale independently from the Manager and can keep running if the Manager goes down. Supported gateway platforms are Vert.x, WildFly, and Tomcat. Standard policies cover authorization, BASIC authentication, IP allowlisting and blocklisting, OAuth2/JWT through the Keycloak plugin, and HTTP security headers. Apiman is licensed under Apache License 2.0, with no features behind paywalls. It is primarily an HTTP gateway: WebSockets lack explicit testing or support, while raw TCP, raw UDP, and messaging protocols are unsupported. Version 3.x is community-supported; versions 2.x and 1.x are unsupported. Commercial support packages are also described as including 24/7 support and CVE patching and alerts.

ReadMe is a web service for publishing documentation to internal and external audiences. Its plans organize content by projects and published versions. Starter is free for everyone and includes one project, one published version, 24 hours of request history, and 24 hours of detailed logs. Pro keeps one project, adds unlimited published versions, and costs $250 a month when billed annually; it also includes the same 24-hour history and detailed logs. That plan combines multiple projects, aggregates documentation metrics, removes ReadMe branding, and adds user roles and access control, audit logs, SSO, OAuth, and more. ReadMe supports custom domains, single sign-on, version history, and content analytics. The maker is ReadMe, headquartered in San Francisco, California, United States. The listed platform is web, and a 14-day trial is listed.